Clinical Trial Update: Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for ranibizumab in hemorrhagic choroidal neovascularization, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Choroidal Neovascularization | Phase 1 | Status: COMPLETED | Results posted: 2012-10-19